{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-016314","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.257446+00:00","generated_at":"2026-06-17T06:20:56.923516+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rocket Pharmaceuticals appoints Mark White as CMO; Schwartz shifts to Chief Gene Therapy Officer","bullets":["Mark White appointed Chief Medical Officer effective April 4, 2023; previously Global Franchise Head for Fasenra at AstraZeneca.","Jonathan Schwartz transitions to newly created Chief Gene Therapy Officer, focusing on gene therapy strategy and external opportunities.","White receives $450k base salary, 45% target bonus, and ~$2M equity grant (1/3 options, 2/3 RSUs) with standard vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-016314","json":"https://secwatch.observer/filing/0001140361-23-016314.json","markdown":"https://secwatch.observer/filing/0001140361-23-016314.md","text":"https://secwatch.observer/filing/0001140361-23-016314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/brhc10051024_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:20:56.923516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86e1dd9e68","claim":"Jonathan Schwartz changed role as Chief Gene Therapy Officer at ROCKET PHARMACEUTICALS, INC..","evidence_excerpt":"On April 4, 2023, Jonathan Schwartz transitioned from Chief Medical Officer of Rocket Pharmaceuticals, Inc. (the “ Company ”) to Chief Gene Therapy Officer,","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Gene Therapy Officer"}],"fact_type":"executive_change"},{"claim_id":"9aadaecd86","claim":"Mark White was appointed as Chief Medical Officer at ROCKET PHARMACEUTICALS, INC..","evidence_excerpt":"Additionally, on April 4, 2023, Mark White joined the Company as its new Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}